Eydelman Mikhail's most recent trade in Vaxcyte Inc was a trade of 5,000 Common Stock done at an average price of $21.4 . Disclosure was reported to the exchange on March 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.41 per share. | 05 Mar 2025 | 5,000 | 46,620 | - | 21.4 | 107,050 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 5,000 | 144,497 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 70.39 per share. | 05 Mar 2025 | 2,621 | 43,999 | - | 70.4 | 184,487 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 71.07 per share. | 05 Mar 2025 | 2,267 | 41,732 | - | 71.1 | 161,107 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 72.37 per share. | 05 Mar 2025 | 112 | 41,620 | - | 72.4 | 8,105 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 48,357 | 48,357 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 14,484 | 42,706 | - | 0 | Common Stock | |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.10 per share. | 27 Feb 2025 | 616 | 41,620 | - | 72.1 | 44,414 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 73.02 per share. | 27 Feb 2025 | 470 | 42,236 | - | 73.0 | 34,319 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.41 per share. | 05 Feb 2025 | 5,000 | 33,222 | - | 21.4 | 107,050 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2025 | 5,000 | 149,497 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 91.05 per share. | 05 Feb 2025 | 1,784 | 28,477 | - | 91.1 | 162,437 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 89.95 per share. | 05 Feb 2025 | 1,755 | 30,261 | - | 89.9 | 157,860 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 89.09 per share. | 05 Feb 2025 | 635 | 32,016 | - | 89.1 | 56,571 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 87.77 per share. | 05 Feb 2025 | 571 | 32,651 | - | 87.8 | 50,115 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 91.71 per share. | 05 Feb 2025 | 255 | 28,222 | - | 91.7 | 23,386 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 5,000 | 154,497 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.41 per share. | 06 Jan 2025 | 5,000 | 33,222 | - | 21.4 | 107,050 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 85.73 per share. | 06 Jan 2025 | 3,921 | 28,347 | - | 85.7 | 336,155 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 84.86 per share. | 06 Jan 2025 | 954 | 32,268 | - | 84.9 | 80,953 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 86.52 per share. | 06 Jan 2025 | 125 | 28,222 | - | 86.5 | 10,815 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.41 per share. | 05 Dec 2024 | 5,000 | 33,697 | - | 21.4 | 107,050 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Dec 2024 | 5,000 | 159,497 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 91.91 per share. | 05 Dec 2024 | 3,177 | 29,085 | - | 91.9 | 292,004 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 90.16 per share. | 05 Dec 2024 | 1,435 | 32,262 | - | 90.2 | 129,384 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.06 per share. | 05 Dec 2024 | 475 | 28,222 | - | 92.1 | 43,729 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 92.90 per share. | 05 Dec 2024 | 388 | 28,697 | - | 92.9 | 36,046 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Gift of securities by or to the insider at price $ 0.00 per share. | 05 Dec 2024 | 110 | 28,697 | - | 0 | Common Stock | |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2024 | 26,125 | 26,125 | - | - | Performance Stock Option (right to buy) | |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2024 | 5,000 | 164,497 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.41 per share. | 05 Nov 2024 | 5,000 | 33,623 | - | 21.4 | 107,050 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 106.82 per share. | 05 Nov 2024 | 1,524 | 29,896 | - | 106.8 | 162,788 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 105.72 per share. | 05 Nov 2024 | 1,415 | 31,420 | - | 105.7 | 149,591 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 107.50 per share. | 05 Nov 2024 | 1,273 | 28,623 | - | 107.5 | 136,842 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 104.80 per share. | 05 Nov 2024 | 788 | 32,835 | - | 104.8 | 82,582 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2024 | 5,000 | 169,497 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.41 per share. | 07 Oct 2024 | 5,000 | 33,623 | - | 21.4 | 107,050 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 109.55 per share. | 07 Oct 2024 | 3,147 | 29,004 | - | 109.5 | 344,744 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 108.69 per share. | 07 Oct 2024 | 996 | 32,151 | - | 108.7 | 108,252 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 107.51 per share. | 07 Oct 2024 | 476 | 33,147 | - | 107.5 | 51,175 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 110.51 per share. | 07 Oct 2024 | 314 | 28,690 | - | 110.5 | 34,699 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 111.69 per share. | 07 Oct 2024 | 67 | 28,623 | - | 111.7 | 7,483 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 5,500 | 174,497 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.41 per share. | 01 Oct 2024 | 5,500 | 34,123 | - | 21.4 | 117,755 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 114.37 per share. | 01 Oct 2024 | 3,056 | 29,653 | - | 114.4 | 349,512 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 113.38 per share. | 01 Oct 2024 | 1,414 | 32,709 | - | 113.4 | 160,321 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 115.01 per share. | 01 Oct 2024 | 1,030 | 28,623 | - | 115.0 | 118,462 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 110.15 per share. | 03 Sep 2024 | 2,203 | 28,623 | - | 110.1 | 242,660 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.41 per share. | 03 Sep 2024 | 1,667 | 32,493 | - | 21.4 | 35,690 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 1,667 | 179,997 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 111.57 per share. | 03 Sep 2024 | 715 | 31,251 | - | 111.6 | 79,770 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 110.45 per share. | 03 Sep 2024 | 523 | 31,966 | - | 110.4 | 57,765 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 116.01 per share. | 03 Sep 2024 | 144 | 30,906 | - | 116.0 | 16,705 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 112.66 per share. | 03 Sep 2024 | 122 | 31,129 | - | 112.7 | 13,745 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 117.28 per share. | 03 Sep 2024 | 80 | 30,826 | - | 117.3 | 9,382 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 114.96 per share. | 03 Sep 2024 | 79 | 31,050 | - | 115.0 | 9,082 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 107.75 per share. | 03 Sep 2024 | 4 | 32,489 | - | 107.8 | 431 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2024 | 1,667 | 181,664 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.41 per share. | 01 Aug 2024 | 1,667 | 32,493 | - | 21.4 | 35,690 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 78.80 per share. | 01 Aug 2024 | 1,482 | 31,011 | - | 78.8 | 116,781 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 79.29 per share. | 01 Aug 2024 | 185 | 30,826 | - | 79.3 | 14,668 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 1,667 | 183,331 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.41 per share. | 01 Jul 2024 | 1,667 | 32,493 | - | 21.4 | 35,690 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 75.93 per share. | 01 Jul 2024 | 913 | 31,580 | - | 75.9 | 69,322 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 76.90 per share. | 01 Jul 2024 | 754 | 30,826 | - | 76.9 | 57,982 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 70.97 per share. | 07 Jun 2024 | 335 | 30,826 | - | 71.0 | 23,775 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.41 per share. | 03 Jun 2024 | 1,667 | 32,828 | - | 21.4 | 35,690 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 1,667 | 184,998 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 71.25 per share. | 03 Jun 2024 | 751 | 32,077 | - | 71.3 | 53,510 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 72.37 per share. | 03 Jun 2024 | 656 | 31,421 | - | 72.4 | 47,472 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 73.64 per share. | 03 Jun 2024 | 260 | 31,161 | - | 73.6 | 19,146 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.41 per share. | 01 May 2024 | 1,667 | 32,264 | - | 21.4 | 35,690 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 1,667 | 186,665 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 61.30 per share. | 01 May 2024 | 964 | 31,300 | - | 61.3 | 59,090 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 61.95 per share. | 01 May 2024 | 559 | 30,741 | - | 61.9 | 34,629 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 63.90 per share. | 01 May 2024 | 144 | 30,597 | - | 63.9 | 9,202 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 1,667 | 188,332 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.41 per share. | 01 Apr 2024 | 1,667 | 32,264 | - | 21.4 | 35,690 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 66.59 per share. | 01 Apr 2024 | 1,397 | 30,867 | - | 66.6 | 93,032 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 67.41 per share. | 01 Apr 2024 | 270 | 30,597 | - | 67.4 | 18,202 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 10,500 | 31,210 | - | 0 | Common Stock | |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 1,667 | 189,999 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.41 per share. | 29 Feb 2024 | 1,667 | 32,877 | - | 21.4 | 35,690 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 73.59 per share. | 29 Feb 2024 | 703 | 31,655 | - | 73.6 | 51,734 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 71.55 per share. | 29 Feb 2024 | 613 | 30,597 | - | 71.5 | 43,860 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 73.03 per share. | 29 Feb 2024 | 519 | 32,358 | - | 73.0 | 37,900 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 74.77 per share. | 29 Feb 2024 | 445 | 31,210 | - | 74.8 | 33,273 | Common Stock |
| Vaxcyte Inc | Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.41 per share. | 01 Feb 2024 | 1,667 | 22,377 | - | 21.4 | 35,690 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 1,667 | 191,666 | - | - | Stock Option (Right to Buy) | |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 73.16 per share. | 01 Feb 2024 | 638 | 21,527 | - | 73.2 | 46,679 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 75.39 per share. | 01 Feb 2024 | 474 | 20,710 | - | 75.4 | 35,735 | Common Stock |
| Vaxcyte Inc | Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 74.11 per share. | 01 Feb 2024 | 343 | 21,184 | - | 74.1 | 25,420 | Common Stock |
| Vaxcyte Inc | Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 72.22 per share. | 01 Feb 2024 | 212 | 22,165 | - | 72.2 | 15,310 | Common Stock |
| Vaxcyte Inc | Eydelman Mikhail | SVP, Gen Counsel & Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 1,667 | 193,333 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Mikhail Eydelman | SVP, Gen Counsel & Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.41 per share. | 02 Jan 2024 | 1,667 | 22,377 | - | 21.4 | 35,690 | Common Stock |
| Vaxcyte Inc | Mikhail Eydelman | SVP, Gen Counsel & Corp Sec | Sale of securities on an exchange or to another person at price $ 64.31 per share. | 02 Jan 2024 | 928 | 20,710 | - | 64.3 | 59,680 | Common Stock |
| Vaxcyte Inc | Eydelman Mikhail | SVP, Gen Counsel & Corp Sec | Sale of securities on an exchange or to another person at price $ 63.59 per share. | 02 Jan 2024 | 598 | 21,638 | - | 63.6 | 38,029 | Common Stock |
| Vaxcyte Inc | Eydelman Mikhail | SVP, Gen Counsel & Corp Sec | Sale of securities on an exchange or to another person at price $ 62.91 per share. | 02 Jan 2024 | 141 | 22,236 | - | 62.9 | 8,871 | Common Stock |
| Vaxcyte Inc | Eydelman Mikhail | SVP, Gen Counsel & Corp Sec | Sale of securities on an exchange or to another person at price $ 56.50 per share. | 07 Dec 2023 | 10,000 | 21,035 | - | 56.5 | 565,000 | Common Stock |
| Vaxcyte Inc | Eydelman Mikhail | SVP, Gen Counsel & Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2023 | 10,000 | 195,000 | - | - | Stock Option (right to buy) |